CFG
VRTX icon

Carr Financial Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Carr Financial Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Buy
+417
New +$185K 0.05% 174
2025
Q3 		– Sell
-528
Closed -$235K – 202
2025
Q2 		$235K Sell
528
-80
-13% -$36.9K 0.07% 168
2025
Q1 		$295K Buy
+608
New +$283K 0.1% 138

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Carr Financial Group's VRTX Position: Q2 2026 in Review

Carr Financial Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 417 shares worth $207K. The stake represents 0.05% of the portfolio and ranks #174 among its holdings. This is a return to the name: Carr Financial Group previously reported a position in VRTX as recently as Q2 2025.

Carr Financial Group first reported a position in VRTX in Q1 2025 and has held it in 3 quarters since. The position peaked at $295K in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Carr Financial Group held 417 shares of Vertex Pharmaceuticals worth $207K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Carr Financial Group position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.05% of Carr Financial Group's portfolio in Q2 2026, its #174 holding.
  • Carr Financial Group first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Carr Financial Group's Vertex Pharmaceuticals position peaked at $295K in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Carr Financial Group's 13F filing for Q2 2026, filed 6 Aug 2026.